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ARF proteins mediate insulin-dependent activation of
phospholipase D
Kuntala Shome, Chandrasekaran Vasudevan and Guillermo Romero
Background: ADP-ribosylation factors (ARFs) have been shown to activate
phospholipase D (PLD), an enzyme modulated by extracellular signals, including
several growth factors and, in particular, insulin. We have tested the hypothesis
that ARF proteins are involved specifically in insulin-induced activation of PLD. 
Results: We found that in membranes obtained from HIRcB cells, a cell line
derived from Rat-1 fibroblasts that overexpresses normal human insulin receptors,
binding of the GTP analogue GTPgS to purified bovine or recombinant ARF was
enhanced in the presence of insulin. Membranes obtained from cells that
overexpressed a mutated, nonfunctional insulin receptor failed to stimulate ARF
activation. Insulin promoted the association of ARF proteins with membranes in
the presence of GTPgS in permeabilized cells. Insulin activated PLD in
permeabilized HIRcB cells by a process that required GTPgS and ARF.
Azido–g[32P]-GTP labelling of immunoprecipitated receptors revealed the
presence of a unique 19 kD band; ARF proteins are approximately this size, and
analysis using specific monoclonal antibodies demonstrated that ARF proteins
coimmunoprecipitated with the insulin receptor. Coimmunoprecipitation of ARF
with the receptor was inhibited by guanine nucleotides and stimulated by insulin.
No evidence of the coprecipitation of ARF with mutant receptors could be
obtained using azido–g[32P]-GTP or anti-ARF antibodies. 
Conclusions: The activation of ARF proteins is stimulated by insulin and this
process plays an important role in insulin-mediated regulation of PLD. 
Background 
ADP-ribosylation factors (ARFs) activate phospholipase D
(PLD) in the presence of GTP analogues in vitro [1]. PLD
catalyzes hydrolysis of phosphatidylcholine to phosphatidic
acid and choline, and is activated by a number of growth
factors, including insulin [2–8]. But although support is
mounting for the idea that ARF proteins may play an
important role in the signal transduction mechanisms by
which growth factors, cytokines and hormones modulate
PLD activity, no evidence of the activation of ARF by
tyrosine kinase receptors has been reported to date.
Two mammalian PLD genes, PLD1 and PLD2, have been
cloned recently [9–11]. The product of one of these genes,
PLD1, is regulated by small GTP-binding proteins and
protein kinase C [9,10]. Plasma membrane preparations
reportedly contain a PLD activity that is significantly
stimulated by ARF and Rho [12,13], but the relationship
of this PLD activity to PLD1 or PLD2 has not been
established. There is as yet relatively little information on
the mechanism of activation of Rho and ARF proteins by
extracellular signals. A few recent reports have suggested
that ARF proteins may be activated by cell surface recep-
tors [14–16], and several ARF guanine-nucleotide
exchange factors have been described recently, some of
which appear to be recruited to the cell membrane via
pleckstrin homology domains [17,18]. A direct demonstra-
tion of receptor-mediated activation of ARF proteins is
still lacking, however. Furthermore, there is no evidence
of the involvement of ARF in the activation of PLD by
receptor tyrosine kinases.
Recently, Karnam et al. [19] suggested that translocation of
ARF and Rho to the plasma membrane can be stimulated
by insulin in rat adipocytes. One of their major conclusions
was that Rho is activated by insulin and that this process
plays an important role in the modulation of PLD activity
by insulin; the activation of ARF was not examined,
however. Here, we have investigated the involvement of
ARF proteins in the insulin-mediated activation of PLD.
The rationale of the approach was that stimulation of cells
with insulin should activate ARF proteins if ARF proteins
are involved in insulin-mediated PLD activation; also,
depletion of ARF should inhibit insulin-induced activation
of PLD; and addition of ARF proteins to ARF-depleted
cells should reconstitute insulin-sensitive PLD activity.
We have addressed these issues using a model system
consisting of Rat-1-fibroblast-derived cell lines that
overexpress either wild-type human insulin receptors
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(HIRcB cells) or mutated, tyrosine-kinase-deficient human
insulin receptors (A/K1018 cells) [20,21]. We report here
that insulin stimulates PLD activity in HIRcB cells, and
that this process is mediated by ARF proteins. We also
show that insulin-treated HIRcB cell membranes and par-
tially purified receptors obtained from these cells can acti-
vate ARF proteins in vitro. Finally, we have examined the
mechanism of activation of ARF by the insulin receptor.
Our data show that macromolecular complexes are formed
at the membrane involving the insulin receptor, ARF and
perhaps additional adaptor proteins. 
Results
Binding of GTPgS to ARF is activated by insulin-treated cell
membranes 
We examined the activation of purified bovine ARF by
HIRcB cell membrane preparations using a reconstitution
assay similar to that described by Randazzo et al. [22]. In
these experiments, a purified bovine ARF preparation was
incubated with membranes that had either been treated
with insulin in the presence of ATP or left untreated.
Insulin-treated HIRcB cell membranes stimulated the
binding of GTPg[35S] to purified bovine ARF (Fig. 1 shows
data obtained with bovine brain ARF; very similar results
were obtained with recombinant, myristoylated human
ARF1). The observed rates of GTPgS binding to ARF in
the presence of insulin-treated membranes are comparable
to those previously reported using ARF and purified Golgi
membranes in similar reconstitution systems [22–24]. 
Figure 1b shows the amount of GTPgS bound after a
30 minute incubation of cell membranes with or without
ARF under the conditions indicated. The data were ana-
lyzed by analysis of variance (ANOVA) followed by pairwise
post-test comparisons using a Bonferroni test. Although the
cell membranes alone appeared to have a small effect on
binding of GTPgS to ARF, this was not statistically signifi-
cant. Insulin pretreatment of the membranes increased the
binding of GTPgS to ARF-reconstituted cell membranes
significantly (p < 0.01), but not the binding of GTPgS to
membranes alone. This effect was completely abolished by
brefeldin A (BFA), a fungal metabolite that blocks ARF
activation by Golgi membranes [22–24].
The effects of insulin on the activation of ARF were
studied, using membranes obtained from A/K1018 cells
that express a human insulin receptor which is mutated at
the ATP-binding site and lacks tyrosine kinase activity
(Fig. 1c). Neither insulin-treated nor naive, untreated
A/K1018 membranes were able to stimulate binding of
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Activation of purified bovine ARF by membranes from HIRcB and
A/K1018 cells. HIRcB cell membranes (10 mg) were treated as
follows: boiled membranes were incubated at 100°C for 5 min; insulin-
treated membranes were incubated with insulin (100 nM), ATP (1 mM)
and MgCl2 (3 mM) for 10 min; BFA-treated membranes were
incubated with BFA for 5 min prior to any subsequent treatment. (a)
Time course of the binding of GTPgS to bovine ARF. Bovine ARF
(8 mg) was added 2–5 min before the binding reaction was started by
addition of GTPg[35S]. Aliquots were taken at various time points and
the amount of bound nucleotide was determined by liquid scintillation
counting of the material retained in nitrocellulose filters. (b) HIRcB
membranes (Mem) treated as in (a) were incubated with ARF for
30 min and with insulin (Ins) where shown. Statistical analysis of the
samples was performed using analysis of variance (ANOVA) followed
by Bonferroni post-test comparisons. The asterisk denotes that the
difference of this sample and others is statistically significant; ANOVA
revealed that there were no statistically significant differences among
the remaining samples. (c) A/K1018 cell membranes treated as
indicated were incubated with or without ARF for 30 min in the
presence of GTPg[35S]. Experiments were repeated at least four times.
GTPgS to ARF under the conditions of the reconstitution
assay. Thus, the effects of insulin on the activation of ARF
by membranes require a receptor with an intact, functional
ATP-binding site. Although ATP and Mg2+ were included
in all assays shown in Figure 1, we do not believe that the
activation of ARF required the tyrosine kinase activity of
the receptor: in some experiments, the non-hydrolyzable
ATP analogue AMPPCP was used instead of ATP and
identical results were observed (data not shown).
Insulin and GTPgS promote the binding of ARF proteins to
cell membranes 
The data described above show that ARF can be activated
by cell membranes in an insulin-dependent manner. An
additional approach was used to confirm these initial obser-
vations. Activated (GTP-bound) ARF proteins are mem-
brane-bound, whereas the GDP-bound form of these
proteins is cytosolic. Thus, ARF–GDP complexes leak out
of cells after treatment with digitonin (a cell-membrane
permeabilizing agent), whereas ARF–GTP complexes do
not [15]. Figure 2 shows that simultaneous treatment with
insulin and GTPgS prevented the leakage of ARF from
digitonin-treated cells. HIRcB cells were serum starved and
treated with digitonin in the presence or absence of insulin
and GTPgS, and the presence of ARF in the supernatants
and cell pellets was determined by immunoblotting.
Untreated cells did not release ARF, whereas digitonin-
treated cells released a large fraction of their ARF content,
which appeared as a prominent band in the supernatant
sample. Cells treated with digitonin in the presence of
GTPgS released a slightly smaller fraction of ARF. Addi-
tion of insulin during digitonin treatment had no effect.
However, the release of ARF from cells treated with digi-
tonin in the presence of both insulin and GTPgS was negli-
gible, with almost all ARF remaining in the pellet sample.
Thus, treatment with insulin and GTPgS induces binding
of ARF to cell membranes. 
The effects of GTPgS alone on binding of ARF to mem-
branes were significantly less obvious than those reported
by others [15,16,25]. A major difference between our assay
and those reported previously is that we used cells that
were serum-starved for about 20 hours to obtain proper
baseline levels for ARF and PLD activity, whereas the
others used membranes or permeabilized cells that had not
been subjected to prolonged serum starvation. In order to
address this issue experimentally, the effects of insulin on
PLD activity and ARF translocation were examined in cells
that had not been serum starved and were compared to the
effects observed in serum-starved cells. Consistent with our
explanation, GTPgS alone was sufficient to promote signif-
icant binding of ARF to membranes and PLD activity in
cells that had not been serum starved, regardless of the
presence of insulin (data not shown).
ARF proteins mediate insulin-induced PLD activation
Figure 3 demonstrates that insulin activates PLD in HIRcB
cells (Fig. 3a) and that ARF proteins are likely to be
involved in this process (Fig. 3b,c). HIRcB cells were
treated with digitonin under the same conditions described
for Figure 2. PLD activity paralleled the ARF release
results (compare Figs 2 and 3). Insulin and GTPgS had a
significant effect on PLD activity only when both were
included in the permeabilization medium. Cells treated
with digitonin in the absence of GTPgS and insulin (condi-
tions in which macromolecules such as ARF may leak out of
the cell as shown in Fig. 2) lost their ability to respond to
insulin and GTPgS added after permeabilization. These
observations demonstrate that the combined effects of
insulin and GTPgS on the activation of PLD require
soluble factors that are removed during permeabilization
with digitonin; they do not prove, however, that the missing
factor(s) are ARF proteins. Nevertheless, as shown in
Figure 3c, the addition of recombinant ARF to these
cytoplasm-depleted cells reconstituted the sensitivity of
PLD to insulin and GTPgS. Recombinant ARF and
GTPgS together had no significant effects on PLD activity
in the absence of insulin. The activation of PLD by the
insulin signalling system therefore requires GTPgS and
soluble cytosolic factors, and in addition, ARF alone is
sufficient to restore insulin- and GTPgS-sensitive PLD
activity in cytosol-depleted HIRcB cells. These observa-
tions were made in serum-starved cells: as stated above,
insulin had no effects in cells that had not been previously
serum starved.
A recent report has suggested that activation of PLD by
insulin in rat adipocytes is likely to be mediated by Rho
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Figure 2
Insulin stimulates the binding of ARF to cell membranes in digitonin-
treated HIRcB fibroblasts. After serum starvation, HIRcB cells were
gently scraped, resuspended in PBS and permeabilized with digitonin
(Dig; 8 mM) where indicated. GTPgS (100 mM) and/or insulin (Ins;
100 nM) were included in the permeabilization buffer for some
samples, as indicated. After incubation at 37°C for 10 or 20 min, the
cells were centrifuged for 15 min in a microcentrifuge. Supernatants
and pellets were collected, resolved by SDS–PAGE and
electroblotted. ARF was detected using the monoclonal antibody 1D9,
followed by chemiluminescence.
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proteins [19]. This was based primarily on the effects of
Clostridium botulinus exotoxin C3, a bacterial toxin that cat-
alyzes the ADP-ribosylation of Rho and appears to prevent
its interaction with downstream effectors. We failed to
detect any effects of exotoxin C3 on the activation of PLD
by insulin in intact HIRcB fibroblasts (data not shown). In
marked contrast, BFA, which acts primarily as an inhibitor
of ARF activation, completely blocked the effects of insulin
on the activation of PLD (Fig. 4). The effects of BFA were
acute and 10 minute incubations with the inhibitor were
sufficient to cause complete inhibition of PLD activity. In
contrast, the studies of Karnam et al. [19] involved treatment
with C3 exotoxin for at least 3 hours. These results suggest
that ARF, rather than Rho, is the principal mediator of the
activation of PLD by insulin in HIRcB cells.
The insulin receptor forms a complex with ARF proteins 
We have shown that insulin induces activation of PLD by a
mechanism that involves activation of ARF proteins. We
thus decided to examine more closely the mechanism by
which the insulin receptor activates ARF. A hallmark of the
mechanism of most tyrosine kinase receptors is the forma-
tion of macromolecular complexes comprising the receptor,
adaptor and target proteins. Hence, we examined the for-
mation of macromolecular complexes involving the insulin
receptor and ARF proteins. Initially, the insulin receptors
of HIRcB cells were immunoprecipitated either with 83-7,
a monoclonal antibody that specifically recognizes the a
subunit of the human insulin receptor [26], or with insulin
immobilized in agarose. We looked for putative guanine-
nucleotide binding proteins in the immunoprecipitate using
azido–g[32P]-GTP, a universal detection reagent which
390 Current Biology, Vol 7 No 6
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ARF and GTPgS are required for insulin-dependent activation of PLD in
digitonin-permeabilized cells. The data are expressed as the number of
counts obtained from the phosphatidybutanol (PtdBu) spot normalized
by the total number of counts of lipid. (a) Insulin stimulates PLD activity
in serum-starved, intact HIRcB cells. (b) Cells were serum-starved for
20 h and permeabilized with digitonin in the presence of the indicated
agents (100 mM GTPgS and/or 100 nM insulin) and butanol (final
concentration of 0.3%) for 20 min at 37°C. (c) Cells were serum starved
for 20 h and permeabilized with digitonin in the presence of butanol for
20 min. At the end of the incubation, cells were washed and incubated
for an additional 20 min with insulin (100 nM), GTPgS (100 mM),
recombinant hARF1 (rhARF1; 6 mg ml–1) or a combination of these
agents as indicated. Data in (a) were analyzed by Student’s t test,
whereas data in (b,c) were analyzed by ANOVA followed by Bonferroni
post-test pairwise comparisons to the respective control groups. All
experiments were repeated at least three times.
Figure 4
Brefeldin A inhibits the activation of phospholipase D by insulin. Cells
were serum starved and pre-labelled with [3H]-palmitate as described
in Materials and methods and incubated with BFA at the
concentrations indicated for 10 min before the addition of insulin. PLD
activity was determined as described in the legend to Figure 3.
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
P
td
B
u 
(%
 to
ta
l l
ip
id
)
Co
ntr
ol Ins
Ins
 + 
BF
A 
(2
5 µ
g m
l–
1 )
Ins
 + 
BF
A 
(5
0 µ
g m
l–
1 )
Ins
 + 
BF
A 
(1
00
 µg
 m
l–
1 )
efficiently labels small and heterotrimeric G proteins and is
crosslinked to these proteins on irradiation with ultraviolet
light. Although we occasionally found a single 32P-labelled
band, typical results (Fig. 5; Irradiated lane) suggested the
presence of several labelled bands in the immunoprecipi-
tate. Nonimmune IgG controls failed to immunoprecipitate
any putative GTP-binding proteins. Addition of GTPgS
(100 mM) to the incubation mixture prevented labelling of
these protein bands. The non-hydrolyzable ATP analogue
AMPPCP (1 mM) inhibited the labelling of all but one of
these bands, a 19 kD component. These results were con-
sistent and show that only this 19 kD protein binds specifi-
cally to guanine nucleotides. This led us to conclude that
the insulin receptor coprecipitates with at least one small
GTP-binding protein and that heterotrimeric G proteins do
not interact with the insulin receptor under the conditions
tested. Mutant insulin receptors solubilized from A/K1018
cells failed to coimmunoprecipitate any putative GTP-
binding proteins (data not shown).
Further investigations into the nature of the GTP-binding
proteins coprecipitated with the insulin receptor were
carried out using specific antibodies against small GTP-
binding proteins. In a typical immunoprecipitation experi-
ment, receptors from 5 × 106 cells were solubilized and
immunoprecipitated. The total number of insulin-binding
sites immunoprecipitated was estimated from [125I]-insulin
binding data and compared with the total number of GTP-
binding sites obtained from analysis of GTPg[35S] binding.
Approximately 10–12 pmol insulin-binding sites were rou-
tinely immunoprecipitated by this procedure, suggesting
that the recovery of immunoprecipitated receptor was
quantitative (HIRcB cells express about 106 receptors per
cell). The ratio of GTPgS-binding sites to insulin-binding
sites was 0.15–0.2, suggesting that 15–20% of the precipi-
tated receptors were associated with GTP-binding proteins.
To further examine the nature of the GTP-binding pro-
teins coimmunoprecipitated with the insulin receptor, the
solubilized receptor was bound to immobilized monoclonal
antibody 83-7 and the bound material analyzed by
SDS–PAGE. Proteins were blotted onto nitrocellulose and
the resulting blots probed with the monoclonal antibody
CT-1, which recognizes the carboxyl terminus of the b
subunit of the insulin receptor [26], as an internal control of
the efficiency of the immunoprecipitation procedure. Blots
were also probed with the following anti-GTP-binding
protein antibodies: Y13-259 and Y13-238 (both of which
recognize Ras proteins); commercially available antibodies
specific for RhoA and RhoB; and a specific anti-ARF anti-
body, 1D9 [27]. Only the anti-ARF antibody showed any
immunoreactivity against the material coprecipitated with
the receptor (Fig. 6; negative results are not shown). These
findings demonstrate that ARF coimmunoprecipitates with
the insulin receptor whereas Ras and Rho proteins do not. 
Coimmunoprecipitation of ARF with the insulin receptor
was greatly enhanced by addition of insulin to the solubi-
lization and immunoprecipitation buffers (Fig. 6a). Stimu-
lation of the cells with insulin before solubilization had
relatively little effect on the efficiency of the coimmuno-
precipitation of ARF with the receptor from the HIRcB
cell lysates and the effects of insulin were observed only
when the hormone was present during both solubilization
and immunoprecipitation. This suggests that the interac-
tions of ARF with the insulin receptor complex are
reversible, such that the complex dissociates on prolonged
incubation in the absence of insulin. We also examined
insulin receptors precipitated with insulin–agarose from
HIRcB cell lysates (Fig. 6b). Controls for the experiments
shown in Figure 6b were obtained by addition of 10 mM
free insulin to the affinity binding reaction. Free insulin
prevented both binding of the insulin receptor to the affin-
ity agarose beads and precipitation of ARF. This leads us
to conclude that the presence of ARF in the material
coprecipitated with the insulin receptor using either mono-
clonal antibody 83-7 or immobilized insulin is the result of
specific interactions of ARF with either the insulin recep-
tor or a protein associated with it. ARF could not be
Research Paper  ARFs mediate PLD activation Shome et al.    391
Figure 5
Azido–g[32P]-GTP labelling of proteins coimmunoprecipitated with the
insulin receptor. Receptors were precipitated with antibody 83-7 and the
precipitated material crosslinked with azido–g[32P]-GTP (7.5 mM,
9.4 Ci mmol–1) for 10 min on ice as described in Materials and methods.
Labelling was performed in the presence of 100mM unlabelled GTPgS
and in the presence of 1 mM AMPPCP where indicated. The film was
exposed overnight. Equivalent results were obtained in four independent
experiments. Protein sizes in kDa are shown on the left.
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detected in the insulin–agarose-precipitated tyrosine
kinase-defective receptors obtained from A/K1018 cell
lysates (Fig. 6c), suggesting that, consistent with the obser-
vations from studies performed using A/K1018 cell mem-
branes, A/K1018 receptors are not coupled to ARF proteins. 
A common feature of most activators of GTP-binding
proteins is that they bind preferentially to the nucleotide-
free form of their targets [28–30]. Thus, activators are
known to decrease the affinity of GTP-binding proteins for
guanine nucleotides and, conversely, guanine nucleotides
reduce the affinity of GTP-binding proteins for their
respective activators. Figure 6d shows that, when guanine
nucleotides were included in the solubilization and affinity
binding buffers, insulin receptors precipitated with
insulin–agarose failed to coprecipitate ARF proteins. This
suggests that guanine nucleotides significantly reduce the
affinity of ARF for the insulin receptor complex and, there-
fore, that the coprecipitation of ARF with the insulin recep-
tor is probably the result of the interaction of ARF with a
specific nucleotide exchange factor. 
Activation of recombinant human ARF1 by
immunoprecipitated insulin receptors
An immunoprecipitation assay developed by Buday and
Downward [31] to study Ras activation in vitro was adapted
to prove that an ARF nucleotide exchange factor was
present in the insulin receptor immune complexes. We
studied the binding of GTPgS to recombinant human
ARF1 (rhARF1) in the presence or absence of insulin
receptor immunoprecipitates. When insulin was omitted
from the immunoprecipitation buffer, the purified receptors
had no effect on the binding of GTPgS to rhARF1, regard-
less of whether insulin was present in the GTPgS binding
buffer (Fig. 7a). However, receptors immunoprecipitated in
the presence of insulin had a remarkable stimulatory effect
on the rate of binding of GTPgS to rhARF (Fig. 7b). These
results suggest that the insulin receptor does not stimulate
the activation of ARF directly and that a third component,
which shows enhanced binding to the insulin receptor in
the presence of insulin, is the actual stimulator of GTPgS
binding. However, we cannot rule out at this time the possi-
bility that the presence of insulin might protect the solubi-
lized insulin receptor from partial denaturation during the
immunoprecipitation procedure.
Discussion
The discovery that ARF proteins activate PLD in vitro has
generated some speculation about the actual role of ARF in
receptor-mediated PLD regulation. ARF proteins have
been associated with both vesicle transport within the Golgi
complex and between the endoplasmic reticulum and Golgi
complex [32], as well as with endosome fusion [33], recep-
tor-mediated endocytosis [34] and several other processes
related to intracellular membrane transport. With the
exception of ARF6, which is permanently bound to the
392 Current Biology, Vol 7 No 6
Figure 6
Investigation of the GTP-binding proteins coimmunoprecipitated with
the insulin receptor. Cell lysates were precipitated with monoclonal
antibody 83-7 or insulin–agarose as indicated, and electroblotted
onto nitrocellulose filters. The upper half of each blot was developed
with the monoclonal antibody CT-1 (which recognizes the b subunit
of the insulin receptor) detecting the 95 kDa band; the lower half of
each blot was developed with the anti-ARF antibody 1D9, which
detects the 19 kDa species. Whole cell lysates and material bound to
the immobilized insulin resin in the presence of excess free insulin
were included as controls. (a) Insulin enhances the association of
ARF with the insulin receptor. The control immunoprecipitation from
HIRcB lysates was carried out using 10 mg non-immune mouse IgG.
The other immunoprecipitations used the monoclonal antibody 83-
7(2 mg) with or without insulin (100 nM). These experiments were
repeated independently four times. (b) Immunoprecipitations from
HIRcB cell lysates using insulin–agarose in the presence of 10 mM
free insulin where indicated. (c) ARF does not coimmunoprecipitate
with A/K1018 receptors. A/K1018 cells were lysed as described in
Materials and methods and the insulin receptors were precipitated
using insulin–agarose in the presence of 10 mM free insulin where
indicated. (d) Guanine nucleotides decrease the affinity of ARF for
the insulin receptor. HIRcB cell lysates were precipitated with
insulin–agarose. Guanine nucleotides and 2 mM MgCl2 were included
during the affinity binding reaction where indicated (100 mM GDP;
100 mM GTPgS).
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plasma membrane, ARF proteins have been found either
dispersed in the cytosol or associated with Golgi mem-
branes [34–36]. A link between ARF activation and recep-
tor signalling has therefore been difficult to conceptualize
and very little attention has been paid to the potential role
of ARF proteins in the processing of extracellular signals.
Our data strongly suggest that there is a functional relation-
ship between the insulin receptor and the activation of
ARF proteins which results in the stimulation of PLD. We
show that the binding of GTPgS to ARF is stimulated by
insulin-treated membranes at levels that are comparable to
those reported for stimulation by Golgi membranes [22–24].
We also show that, as for Golgi membranes, activation of
ARF by insulin-treated membranes is BFA-sensitive. Fur-
thermore, activation of ARF proteins by insulin-treated
membranes requires a functional insulin receptor: tyrosine-
kinase negative receptor mutants fail to catalyze the
binding of GTPgS to ARF. We also show that ARF is
required for insulin-mediated PLD activation. Thus, our
data are consistent with a role for ARF proteins in specific
signalling mechanisms. Finally, our data suggest that ARF
interacts with the insulin receptor, either directly or via an
unknown adaptor protein, thus suggesting a mechanism by
which the insulin receptor, and perhaps other related recep-
tor tyrosine kinases, may regulate PLD activity.
An intriguing aspect of our studies is that activation of ARF
by the insulin receptor does not require ATP hydrolysis.
Non-hydrolyzable ATP analogues could substitute for ATP
in all assays performed, and ATP was not required for acti-
vation of ARF or PLD in digitonin-treated (permeabilized)
cells. In contrast, mutant A/K1018 insulin receptors failed to
interact with ARF proteins in reconstitution or immunopre-
cipitation assays. These mutants have no tyrosine kinase
activity because lysine 1018 is replaced by an alanine. As
K1018 is one of the critical amino acids of the ATP-binding
site of the b subunit of the receptor [20], A/K1018 mutants
not only lack tyrosine kinase activity but also exhibit very
little affinity for ATP. Our data suggest that activation of
ARF proteins and PLD by insulin receptors requires an
intact ATP-binding site but does not require autophospho-
rylation or tyrosine kinase activity.
A second interesting aspect of our studies using digitonin-
treated cells is that short incubations with GTPgS alone did
not promote binding of ARF to membrane and the combi-
nation of GTPgS and recombinant ARF was not sufficient
to restore the PLD activity of ARF-depleted cell pellets.
These observations were repeated many times with invari-
able results. However, our data appear to contradict some
previous reports which indicate that GTPgS promotes
binding of ARF to membranes [16,25] and that recombi-
nant ARF and GTPgS alone are sufficient to reconstitute
PLD activity [1,9,16]. The explanation for these discrep-
ancies appears to be related to different experimental con-
ditions: for instance, all our experiments were carried out
using cells, or membranes from cells, that had been
serum-starved for 20 hours, whereas none of the reports
cited above showed data from serum-starved cells. During
prolonged serum starvation, the levels of some of the
endogenous activators of ARF or PLD, such as PIP2, associ-
ated with the Golgi complex and other cell compartments
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Figure 7
Effects of the immunoprecipitated insulin
receptor preparation on the rate of binding of
GTPgS to recombinant ARF. Human insulin
receptors were immunoprecipitated using
monoclonal antibody 83-7 or non-immune
mouse IgG (Control), with or without insulin
(100 nM). Recombinant human ARF1 (rhARF1)
was prepared from Escherichia coli that
coexpressed wild-type ARF1 and yeast N-
myristoyl transferase. Immunoprecipitated
receptors were incubated with 6 mg hARF1 for
10 min and the binding reaction was initiated by
addition of GTPg[35S] (100 nM, 1 mCi) as
described in Materials and methods. Samples
were centrifuged and the amount of nucleotide
bound to ARF was determined by nitrocellulose
filtration and liquid scintillation counting. (a)
Each receptor preparation was obtained by
incubation of the solubilized HIRcB cell extracts
with the monoclonal antibody 83-7 in the
absence of insulin. Recombinant hARF1 was
present in each sample, and as indicated,
insulin was included in one sample during the
binding reaction. The rate of binding of GTPgS
was determined from the slopes of the curves
shown and ranged from 0.0012 ± 0.0006
pmol min–1 to 0.0027 ± 0.0006 pmol min–1
with no statistically significant differences
between treatments. (b) The receptors used in
these experiments were obtained by
immunoprecipitation from HIRcB cell extracts in
the presence of 100 nM insulin. The figure
shows the data obtained in the absence of
added rhARF for comparative purposes only.
The rate of binding of GTPgS to rhARF as
calculated from these data was 0.023 ± 0.003
pmol min–1, that is 10 times greater than the
rate of GTPgS binding determined in the
presence of receptors isolated in the absence
of insulin (a). These experiments were repeated
four times with independent samples and the
observed acceleration of the GTPgS binding
reaction varied from 10–20-fold under the
conditions described. ANOVA and post-test
comparisons of the slopes obtained
demonstrated that only the receptors
immunoprecipitated in the presence of insulin
had a significant effect on the kinetics of
GTPgS binding to rhARF1 under these
experimental conditions.
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might be reduced. To investigate whether the observed dif-
ferences might be related to whether the cells had been
subjected to prolonged serum starvation, we determined
PLD activity and ARF membrane-binding in cells that had
not been serum starved. Our observations showed that in
the absence of serum starvation basal PLD activity is high
and that it is not stimulated by insulin; in addition, insulin is
no longer required to promote the binding of ARF to mem-
branes or to activate PLD in the presence of GTPgS and
recombinant ARF in permeabilized cells (data not shown). 
There are multiple mammalian ARF genes and so specific
functions for different members of the family can be envi-
sioned. ARF6 is the only ARF that has been found at the
plasma membrane and would thus be a prime candidate to
play a significant role in receptor signalling [34,36].
However, a specific anti-ARF6 antibody (a gift of P. Stahl)
failed to bind to the ARF protein that coprecipitated with
the insulin receptor in our experiments (data not shown),
although control experiments demonstrated that ARF6 is
abundantly expressed in HIRcB cells. Thus, ARF6 does
not appear to be the major ARF protein associated with the
insulin receptor in HIRcB cells. Furthermore, our reconsti-
tution experiments demonstrate that recombinant human
ARF1 can substitute for endogenous ARF proteins in
insulin-dependent PLD activation. Therefore, ARF pro-
teins other than ARF6 are likely to be involved in insulin
receptor-dependent PLD regulation.
Many questions remain to be addressed regarding the
nature of the interactions of the insulin receptor and ARF.
As insulin is required for the formation of complexes that
include the insulin receptor and ARF proteins, it is appar-
ent that the insulin receptors that interact with ARF are
either in the plasma membrane or in early endocytic vesi-
cles formed shortly after insulin binding. These views are
supported by the recent data of Karnam et al. [19] who have
shown that, in adipocytes, insulin induces a three-fold
increase in the amount of ARF bound to the plasma mem-
brane with no significant changes in the levels of ARF
bound to a microsomal fraction. Furthermore, our data
suggest that the interaction of ARF with the receptor is not
direct and that a putative ARF GDP-exchange factor
(GEF) might be involved. The nature of this putative GEF
remains to be determined, but in view of the recent find-
ings that cytohesin-1 is a GEF for ARF [18] that can be
recruited to the plasma membrane by integrins [37], we
speculate that the putative GEF recruited by the insulin
receptor is a member of the cytohesin family. 
Are both ARF and Rho proteins involved in insulin-
mediated activation of PLD? Current evidence seems to
indicate that there are at least two redundant pathways by
which insulin might activate PLD. One of these involves
the activation of RhoA and phosphoinositide 3′-kinase [19],
and is probably mediated by the tyrosine phosphorylation
of the insulin receptor substrate-1 (IRS-1). The second
pathway involves ARF proteins but does not appear to
require the tyrosine kinase activity of the insulin receptor.
Figure 8 illustrates a working model for the activation of
PLD by insulin through these two parallel pathways. 
Finally, the issue of the specific roles played by ARF in
insulin signalling remains open. ARF (and possibly PLD)
functions are mainly related to the modulation of processes
that involve membrane transport. There are at least two
membrane transport processes that are finely regulated by
insulin: the internalization of the insulin receptor and the
recruitment of glucose transporters to the surface of the cell,
both of which are inhibited by BFA, a potent blocker of the
activation of ARF [38,39]. These studies therefore support
the view that ARF-mediated signalling pathways may play
an important role in insulin function.
Conclusions 
We have investigated the mechanism of activation of PLD
by insulin using fibroblasts that overexpress the insulin
receptor as a model system. We have shown that insulin
activates PLD and ARF proteins in cells that express
wild-type insulin receptors, but not in cells that express
receptors mutated at the ATP-binding site; that ARF pro-
teins can mediate the effects of insulin on PLD activation;
and that ARF proteins form macromolecular complexes
with the insulin receptor by a mechanism that is activated
by insulin, inhibited by guanine nucleotides and appar-
ently requires the presence of specific adaptor proteins. A
simple model that accounts for our observations is the
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Figure 8
A model for the activation of PLD by insulin. Stimulation of the insulin
receptor is proposed to activate two separate pathways of PLD
regulation. One of these is dependent on the tyrosine kinase activity of
the receptor and involves PI 3′-kinase and Rho. The second involves
the recruitment of ARF-GEF, an activator of ARF proteins, to the
membrane by noncovalent interactions.
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following. Upon binding insulin, the insulin receptor may
form a complex with ARF proteins, probably via the recruit-
ment of an ARF activator (ARF-GEF). Upon binding to the
receptor complex, the affinity of ARF for guanine
nucleotides decreases, allowing the dissociation of GDP
from ARF and the replacement of GDP with GTP. As
ARF–GTP spontaneously binds to cell membranes, acti-
vated ARF–GTP complexes bind to intracellular mem-
branes where they modulate several processes, such as the
activation of PLD. 
Materials and methods
Cell culture 
HIRcB and A/K1018 cells were cultured in 100 or 60 mm dishes using
DMEM/F12 supplemented with 10% foetal bovine serum and 100 nM
methotrexate, as described [38]. Cells were used within 3 days of sub-
culture and were serum starved for 20 h in medium containing 0.1%
BSA before treatment. 
Membrane preparations 
Cell membranes were prepared from ten 100 mm dishes of confluent
cells. Cells were washed in phosphate-buffered saline (PBS), scraped,
pelleted by centrifugation, resuspended in 50 mM Hepes (pH 7.6), 8%
sucrose, 10 mM EDTA, 10 mM EGTA and 1 mM PMSF and disrupted
using a glass homogenizer. Cell extracts were layered onto a 41%
sucrose cushion (in Hepes buffer) and centrifuged for 90 min at
95 000 × g for 90 min. Membrane material at the interface was collected,
diluted to 10 ml and centrifuged at 60 000× g for 60 min. The membrane
pellet was resuspended in 50 mM Hepes, diluted to about 1 mg ml–1
protein, aliquoted, and stored at –700C until ready to use. This mem-
brane preparation is relatively crude and may contain a significant amount
of Golgi membranes.
ARF activation assays 
ARF activation was studied by determining the binding of GTPgS to puri-
fied bovine brain ARF or recombinant human ARF1. Bovine ARF was
purified by a procedure essentially identical to that described by Kahn
and Gilman [40]. The ARF protein preparation was further examined by
SDS–PAGE and the presence of contaminant G proteins was examined
by crosslinking an aliquot of the material to azido–g[32P]GTP followed by
SDS–PAGE. Recombinant wild-type human ARF1 was purified from E.
coli that coexpressed the ARF1 gene and yeast N-myristoyl transferase
(a gift of R. Kahn). Enriched plasma membranes were prepared from con-
fluent HIRcB and A/K1018 cells as described above. ARF (4–8mg) and
membranes (10 mg) were incubated with GTPg[35S] (1 mM,
34 mCi mol–1) at 370C in 20 mM Hepes (pH 7.4)/100 mM NaCl/2 mM
MgCl2/0.1% Na cholate/1 mM ATP (200 ml final volume). At the indi-
cated times, 50 ml aliquots were collected and the reaction was
quenched by the addition of 2 ml ice-cold stop buffer (same as above but
containing 10 mM MgCl2 and 100 mM GTPgS) and protein-bound
nucleotide was separated by filtration through nitrocellulose filters.
Bound nucleotide was determined by scintillation counting. Nonspecific
binding was determined using excess unlabelled GTPgS.
Immunoprecipitation and affinity binding assays 
The following antibodies were used in these experiments: 83-7, a mono-
clonal antibody that recognizes specifically the a subunit of the human
insulin receptor; CT-1, a monoclonal antibody that recognizes the car-
boxyl terminus of the b subunit of the insulin receptor ([26]; both of these
were gifts of Peter Isakson, Monsanto). Cells from between one and
three 100 mm plates were washed with cold PBS, scraped, centrifuged
at 1 000 r.p.m. for 5 min in ice-cold PBS and solubilized in 1 ml 50 mM
Hepes pH 7.4 containing 0.1 M NaCl, 1.5% sodium cholate, 1 mM
EDTA, 1 mM EGTA, 5 mg ml–1 leupeptin, 1 mM PMSF and 1 mg ml–1
soybean trypsin inhibitor. After solubilization for 1 h on ice, insoluble
material was removed by centrifugation in a microfuge for 20 min. Insulin
receptors were immunoprecipitated by incubation of aliquots of the cell
lysate (about 1 mg of cell protein) with anti-mouse IgG agarose that had
previously been equilibrated with 2–10mg of monoclonal antibody 83-7.
Affinity purification assays were carried out using insulin–agarose
(Sigma). In these experiments, 50ml of a 50% slurry of the
insulin–agarose gel were washed with solubilization buffer (see above)
and solubilized cell extracts and were used instead of the
antibody–agarose complexes. Immunoprecipitations and affinity precipi-
tations were carried out overnight at 40C or for 2 h at room temperature.
Immunoprecipitates were washed twice with immunoprecipitation buffer,
twice with immunoprecipitation buffer containing 0.1% cholate and once
with cholate-free immunoprecipitation buffer. Control immunoprecipita-
tions were carried out using non-immune mouse IgG. Negative controls
for the affinity-precipitation of the receptor were carried out in the pres-
ence of a large excess (10 mM) of free insulin. In some of the experi-
ments, the effects of additional specific agents such as insulin
(immunoprecipitations only, 100 nM), ATP (1 mM), AMPPCP (1 mM),
GTPgS (100 mM) or GDP (1 mM) were tested. In all cases, these agents
were included in the cell solubilization and immunoprecipitation buffer.
Immunoblotting 
Protein bands resolved by SDS–PAGE were transferred to nitrocellulose
filters. Filters were then cut in half horizontally. The upper part was used to
detect the b subunit of the insulin receptor; the lower half was used to
detect ARF and other small GTP-binding proteins. The filters were
blocked overnight at 40C in blocking buffer (PBS containing 5% non-fat
milk, 0.01% azide and 0.1% Tween). ARF was detected with 2mg ml–1
affinity purified 1D9 (a monoclonal antibody that recognizes most
members of the ARF family [27]; a gift of R. Kahn). Other antibodies used
were: monoclonal anti-Ras antibodies Y13-238 and Y13-259 (affinity
purified from hybridoma culture supernatants, a gift of S. Sebti), anti-RhoA
and anti-RhoB polyclonals (Santa Cruz Biotechnology). The b subunit of
the insulin receptor was detected with the monoclonal antibody CT-1
(1 mg ml–1). Bound antibodies were detected by chemiluminescence.
PLD activity assays 
Cells (100 mm plates; 70–80% confluent) were serum starved and
labelled overnight with 3H-palmitate (5 mCi ml–1) in DMEM/F12. Cells
were stimulated with insulin (100 or 200 nM) in the presence of 0.3%
butanol for 20 min. The reaction was stopped by addition of chloro-
form:methanol (1:1). The lipid phase was extracted and developed by
thin layer chromatography (TLC) on silica gel 60 plates using ethyl
acetate:trimethylpentane:acetic acid (9:5:2) as the solvent. The position
of major phospholipids was determined using true standards (Avanti Bio-
chemicals) and autoradiography. The TLC plates were scraped and the
total amount of radioactivity associated to each lipid species was deter-
mined by liquid scintillation counting. The data are expressed as the
number of counts associated to the phosphatidylbutanol spot normalized
by the total number of counts of lipid. 
Digitonin treatment 
HIRcB cells were serum starved, scraped gently, resuspended in PBS
and treated with 8 mM digitonin in the presence or absence of insulin
(100 nM) and/or GTPgS (100 mM) at 370C for 20 min. Magnesium
(2 mM) and ATP or AMPPCP (2 mM) were included in some of the
experiments. To release intracellular proteins, digitonin-treated cells were
centrifuged in a microfuge for up to 15 min. PLD activity was determined
using cells that had been labelled overnight with 3H-palmitate (see
above). Supernatants and pellets were collected separately and resolved
by SDS–PAGE. ARF proteins were detected by immunoblotting as
described above. PLD activity of the permeabilized cells was determined
as described above.
Crosslinking experiments 
Immunoprecipitated receptors were incubated with azido–g[32P]-GTP
(7.5 mM, 9.4 Ci mmol–1) for 20 min on ice in immunoprecipitation buffer
(50 mM Hepes, pH 7.4, 0.1 M NaCl) containing 2 mM MgCl2. Where
indicated, the reaction mix contained GTPS (200 mM) or AMPPCP
(1 mM). The immunoprecipitated material was incubated with azido–GTP
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for 15 min on ice in the dark to allow binding of the nucleotide to the
immunoprecipitated proteins. Nucleotide was crosslinked to the protein
by a 10 min exposure of the reaction mix to ultraviolet light using a hand
held UV lamp. The protein was denatured by incubation with Laemmli
buffer at 600C for 10 min and resolved by SDS–PAGE in 12.5% acry-
lamide gels. Gels were dried and exposed to X-ray film for 24–72 h. On
some occasions, proteins were transferred to nitrocellulose membranes
before exposure to the X-ray film, as this procedure significantly reduced
the background and generated cleaner results.
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